Login to Your Account



News from ECCMID


Tuesday, April 25, 2017

Polyphor Ltd., of Allschwil, Switzerland, presented data for its OMPTA (outer membrane protein targeting antibiotics) platform, showing a 91 percent clinical cure rate and 9 percent mortality rate in 12 patients treated with lead OMPTA murepavadin, with multiple doses of the drug demonstrating acceptable tolerability.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription